Last viewed: GILD


Prices are updated after-hours



nasdaq:GILD Gilead Sciences, Inc.

GILD | $68.51 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-5.5% 1m) (0.5% 1y) (1.0% 2d) (-0.8% 3d) (-4.1% 7d) (71.8% volume)
http://www.gilead.com
Sec Filling | Patents | 11800 employees

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Drugs
Biktarvy (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
Cayston (aztreonam)
COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
DESCOVY (emtricitabine and tenofovir alafenamide)
Emtriva (EMTRICITABINE)
Epclusa (Velpatasvir and Sofosbuvir)
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Hepsera (adefovir dipivoxil)
ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
Ranexa (RANOLAZINE)
Sovaldi (SOFOSBUVIR)
Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Tybost (COBICISTAT)
Veklury (REMDESIVIR)
VEMLIDY (tenofovir alafenamide)
Viread (TENOFOVIR DISOPROXIL FUMARATE)
Vosevi (SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR)
Zydelig (idelalisib)

add to today's watch list email alert is off




respiratory   liver   urea   antiviral   brands   liver disease  

Press-releases


Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -1.62% H: 0.53% C: -1.72%


JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GLPG | $57.17 | twitter stocktwits trandingview |
Health Technology
| | O: 1.69% H: 0.0% C: 0.0%
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.65% H: 0.0% C: 0.0%

jyseleca treatment era license
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
Published: 2022-01-18 (Crawled : 23:00) - biospace.com/
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.65% H: 0.0% C: 0.0%

financial results ces results
Outlook on the CAR T-cell Therapy Global Market to 2031 - by Product Type, Indications, End-user and Region
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $88.6 | twitter stocktwits trandingview |
Health Technology
| | O: 1.26% H: 0.0% C: 0.0%
SRNE | $3.805 | twitter stocktwits trandingview |
Health Technology
| | O: -5.96% H: 0.0% C: 0.0%
NVS | News | $87.83 | twitter stocktwits trandingview |
Health Technology
| | O: 0.02% H: 0.0% C: 0.0%
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.32% H: 0.0% C: 0.0%
BLUE | $7.24 | twitter stocktwits trandingview |
Health Technology
| | O: -0.57% H: 0.0% C: 0.0%
JNJ | News | $165.98 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%

era cel therapy t-cell
BioSpace Movers & Shakers, Jan. 14
Published: 2022-01-14 (Crawled : 13:30) - biospace.com/
JNJ | News | $165.98 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%
GSK | News | $45.1 | twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 0.0% C: 0.0%
LLY | News | $247.43 | twitter stocktwits trandingview |
Health Technology
| | O: -1.46% H: 0.0% C: 0.0%
AMRX | $4.46 | twitter stocktwits trandingview |
Health Technology
| | O: -1.71% H: 0.0% C: 0.0%
MRTX | News | $117.95 | twitter stocktwits trandingview |
Health Technology
| | O: -2.14% H: 0.0% C: 0.0%
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.32% H: 0.0% C: 0.0%
GLAXF | News | $21.82 | twitter stocktwits trandingview |
Health Technology
| | O: -1.67% H: 3.62% C: 3.62%
PPG | $154.74 | twitter stocktwits trandingview |
Process Industries
| | O: -2.07% H: 0.0% C: 0.0%
AMGN | $227.72 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%
PHAT | $15.15 | twitter stocktwits trandingview |
Health Technology
| | O: -3.08% H: 0.0% C: 0.0%

space spac
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Published: 2022-01-10 (Crawled : 14:30) - biospace.com/
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: 1.02% H: 0.36% C: 0.14%


ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer
Published: 2022-01-10 (Crawled : 20:00) - biospace.com/
ARVL | News | $5.0 | twitter stocktwits trandingview |
Manufacturing
| | O: 1.88% H: 0.0% C: 0.0%
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: 1.02% H: 0.36% C: 0.14%


Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
Published: 2022-01-10 (Crawled : 14:30) - biospace.com/
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: 1.02% H: 0.36% C: 0.14%


Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
FATE | $37.15 | twitter stocktwits trandingview |
Health Technology
| | O: -0.56% H: 2.27% C: -4.25%
AKRO | $19.93 | twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 4.23% C: 3.03%
GLAXF | News | $21.82 | twitter stocktwits trandingview |
Health Technology
| | O: -2.58% H: 1.2% C: 0.05%
LEGN | $39.21 | twitter stocktwits trandingview |
Health Technology
| | O: -7.55% H: 3.65% C: 3.07%
AMGN | $227.72 | twitter stocktwits trandingview |
Health Technology
| | O: -0.64% H: 0.67% C: 0.01%
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: -0.96% H: 0.58% C: -0.12%
XLO | $13.62 | twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 0.33% H: 5.33% C: -4.47%
GSK | News | $45.1 | twitter stocktwits trandingview |
Health Technology
| | O: -0.96% H: 0.0% C: 0.0%

era therapeutics
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-01-04 (Crawled : 01:00) - prnewswire.com
GILD | $68.51 | twitter stocktwits trandingview |
Health Technology
| | O: 0.4% H: 0.0% C: 0.0%

new drug fda application ces drug cancer negative breast cancer
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount
0001127602-21-024266 4 2021-08-24 Buy A 32 29198
0001127602-21-024264 4 2021-08-24 Buy A 1 14080
0001127602-21-024261 4 2021-08-24 Buy A 1 36972
0001127602-21-023999 4 2021-08-18 Sell M 3829 0
0001127602-21-023999 4 2021-08-18 Sell M 9781 5869
0001127602-21-023999 4 2021-08-18 Sell S 13610 20398
0001127602-21-023999 4 2021-08-18 Buy M 3829 34008
0001127602-21-023999 4 2021-08-18 Buy M 9781 30179


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying